Vir Biotechnology Investor Relations Material

Vir Biotechnology Inc., a commercial-stage immunology company, specializes in developing therapeutic products aimed at treating and preventing serious infectious diseases. Leveraging its expertise in immunology, Vir Biotechnology focuses on a wide range of diseases, including viral and bacterial infections, with a particular emphasis on chronic infectious diseases like hepatitis B, tuberculosis, and HIV, as well as respiratory diseases such as influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV). The company's approach involves a multi-program, multi-platform strategy to induce protective and therapeutic immune responses. Vir Biotechnology is headquartered in San Francisco, California, and its shares are listed on the Nasdaq.